Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora (COR) reported an insider equity award. EVP, Chief Data & Info Officer Pawan Verma filed a Form 4 for a grant of 3,963 restricted stock units (RSUs) on 11/12/2025.
The RSUs were received for no consideration and vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028. Each RSU corresponds to one share of Cencora common stock, and the filing lists 3,963 derivative securities beneficially owned Direct (D) following the transaction.
Cencora (COR) Executive Vice President Elizabeth S. Campbell filed a Form 4 disclosing equity changes. On 11/13/2025, she acquired 20,613 shares of common stock at $0 upon performance share unit vesting, and a same‑day withholding transaction covered taxes for 9,532 shares at $312.53.
Separately, on 11/12/2025 she received a grant of 3,523 RSUs that vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028. Following these transactions, she beneficially owned 26,388.141 shares, held directly.
Cencora, Inc. (COR) reported insider equity activity by its SVP & Chief Accounting Officer, Lazarus Krikorian. On 11/13/2025, 2,434 shares of common stock were acquired at $0 upon meeting performance criteria, bringing direct holdings to 21,642 shares. The same day, 1,059 shares were disposed at $312.53 to satisfy tax withholding, resulting in 20,583 shares directly owned after the transactions.
In a separate equity grant, on 11/12/2025 the officer received 2,271 Restricted Stock Units at $0. These RSUs vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora, Inc. (COR) reported insider equity changes for Executive Vice President Silvana Battaglia. On 11/13/2025, she acquired 12,885 shares of common stock at $0 upon the satisfaction of performance criteria tied to prior performance share units, and disposed of 5,612 shares at $312.53 to satisfy tax withholding related to that vesting. Following these transactions, she beneficially owns 19,947.464 common shares, held directly.
Separately, on 11/12/2025, she received a grant of 2,202 Restricted Stock Units at $0, which vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora, Inc. (COR) reported insider activity by Executive Vice President Silvana Battaglia on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock (codes M) for 1,265 shares and 1,084 shares. To cover tax withholding, she had broker-assisted sales (code F) of 551 shares and 473 shares at $360.70 per share. After these transactions, she directly owned 12,674.464 common shares.
The footnotes state the first RSU grant vested in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025, and the second RSU grant vests on 11/08/2024, 11/08/2025, and 11/08/2026. The 2023 grant is fully settled; 1,085 RSUs from the 2024 grant remain outstanding.
Cencora (COR) reported insider activity by an Executive Vice President. On 11/07/2025, two restricted stock unit tranches converted to common stock: 2,023 shares and 1,830 shares (coded “M”). To cover taxes, the filer disposed of 798 shares and 572 shares at $360.7 per share (coded “F”). Following these transactions, directly beneficially owned common stock stood at 15,307.141 shares. The vesting schedules referenced cover installments on 11/09/2023–2025 and 11/08/2024–2026.
Cencora (COR) reported a Form 4 for CFO James F. Cleary reflecting RSU vesting and tax withholding on 11/07/2025. Two RSU tranches converted to common stock: 2,951 shares and 2,439 shares (codes M). To satisfy withholding taxes, the company withheld and disposed of 1,250 shares and 705 shares at $360.7 per share (code F). Following these transactions, Cleary’s directly held common stock totaled 117,728.3479 shares.
The vested RSUs relate to grants scheduled to vest in equal annual installments on 11/9/2023–11/9/2025 and 11/08/2024–11/08/2026, as noted in the filing.
Cencora (COR) reported insider activity by its SVP & Chief Accounting Officer. On 11/07/2025, two restricted stock unit (RSU) tranches vested and were settled into common stock: 1,433 shares and 1,398 shares (both at $0 exercise price).
To cover withholding taxes tied to the vesting, the insider disposed of 411 shares and 366 shares at $360.7 per share. Following these transactions, the insider directly holds 19,208 shares of common stock. The RSUs relate to grants vesting in equal annual installments on 11/09/2023–11/09/2025 and 11/08/2024–11/08/2026.
Cencora, Inc. (COR) reported insider activity by President & CEO and Director Robert P. Mauch on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock: 4,215 shares and 4,065 shares (codes M). To cover taxes upon vesting, the filer disposed of 1,735 shares and 1,673 shares at $360.70 per share (code F). After these transactions, Mauch directly beneficially owns 42,812 shares.
Footnotes indicate the RSUs were granted for no consideration and vest in three equal annual installments tied to November 2023–2026 dates.
COR insider Steven Collis filed a Form 144 to sell up to 50,000 common shares through Fidelity Brokerage Services on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $17,762,553.74 and notes 193,877,881 shares outstanding. The shares derive from restricted stock vesting on 11/12/2014, 11/11/2015, 08/07/2016, 11/11/2018, and 11/14/2018. In the past three months, Collis sold 14,579, 31,350, and 31,350 shares for gross proceeds of $4,227,618.42, $9,087,157.00, and $10,251,104.58, respectively.